Proprietary Probiotic Strain of Bifidobacterium longum for Infant Health
Early life complications and chronic health conditions among children continue to rise over the years. Accumulating evidence shows that microbes residing in the human body play important roles in infant development and immunity system maturation, starting from the first 1000 days and transcendence in later life.
The development of healthy gut microbiota during early life, with a predominance of Bifidobacterium spp., offers an extraordinary window of opportunity for neonatal health development and disease prevention. Aberrant bifidobacterial colonization affected by factors including gestational age, delivery modes, and feeding types may lead to gut disorders, allergies, and obesity later in life.
Consumer recognition of the need to maintain healthy gut microbiota during early life for lifelong well-being is getting stronger and they are seeking probiotics to support infant health. Infant nutrition products are increasingly fortified with probiotics, including bifidobacteria, which are gaining traction worldwide. However, not all bifidobacteria are the same.
A leading Japanese dairy company has developed a premium line of probiotic strains that are highly compatible with the human gut. These strains are natural inhabitants of the human intestines and more superior in physiological functions critical for infant health. Among them, the proprietary strain of Bifidobacterium longum is a well-documented probiotics with proven clinical benefits to infant's and children’s health.
The company is seeking collaborations with infant nutrition, dietary supplement and functional food manufacturers that are interested in enhancing their product offerings in forms of R&D collaborations or cocreations to develop novel products incorporated with this proprietary B. logum strain.